WHO says that the Sinovac COVID vaccine is effective, but that some data are missing Coronavirus pandemic News

The expert group says “quality” data on the harmful effects of the jab is needed as the vaccine has spread from Brazil to Indonesia.

The COVID-19 vaccine, developed by China’s Sinovac Biotech, is effective in preventing COVID-19 among people under the age of 60, but some quality data are lacking from experts from the World Health Organization.

Independent experts in the WHO Strategic Advisory Group of Experts (SAGE) reviewed Sinovac’s CoronaVac jab from phase 3 clinical trials in China, Brazil, Indonesia, Turkey and Chile.

The assessment by WHO’s SAGE experts indicated “very low confidence” in the data provided by Chinese state physician Sinopharm on the COVID-19 vaccine about the risk of serious side effects in some patients but overall confidence in prevention capacity. The disease, according to a document seen by the Reuters news agency, was reported on Wednesday.

SAGE experts say Sinovac vaccine has been authorized in 32 countries and jurisdictions and 260 million doses have been distributed.

“We are very confident that 2 doses of CoronaVac are effective in preventing adult (18-59 year old) PCR from confirmed COVID19,” SAGE said in an assessment published on the WHO website.

He cited mere evidence of safety and security and clinical protection during pregnancy in the assessment of rare adverse events detected in adults with underlying disease and post-authorization safety control.

Experts said they had a “moderate level of confidence” that the risk of serious adverse effects was low among people aged 59 and under, but that they had a “low level of confidence” in the quality that proved that this risk was also low for adults. Over 60.

“We have little confidence in a quality that demonstrates a low risk of serious events against people with comorbidities or health conditions that increase the risk of COVID-19 following a dose or two of CoronaVac,” they added.

A separate team of WHO technical experts was examining Sinovac’s shot on Wednesday to find a potential list for WHO emergencies. This would facilitate the way to use COVAX on a global vaccine sharing platform, but also a crucial protection internationally. China.